Circle Pharma is committed to providing safe, fair, and sustainable patient access to its investigational compounds at different stages of lifecycle development. Circle Pharma is currently planning and conducting clinical trials to assess the potential safety, tolerability, and efficacy of CID-078, which is an investigational compound.

Expanded access and compassionate use programs allow patients to gain access to investigational compounds outside of a clinical trial. Under the 21st Century Cures Act, the manufacturer of a drug for a serious disease or condition may provide the drug to eligible patients under certain conditions.

In order to ensure appropriate access to CID-078 and to safeguard the welfare of clinical trial patients and potential patients, Circle Pharma first needs to confirm that CID-078 is safe, tolerable, and effective through controlled clinical trials. We believe the best way to make CID-078 available to patients is by enrolling and completing all of our clinical trials and pursuing a regulatory approval pathway, thus enabling the broader population to get access.  

Circle Pharma is not making CID-078 available on an expanded access basis at this time. 

 
Circle Pharma reserves the right to update or revise its expanded access policy at any time. For information on any updates or changes to Circle Pharma’s expanded access policy and current clinical studies, please visit www.clinicaltrials.gov or circlepharma.com. Circle Pharma’s publication of this current policy or any future policy shall not serve as a guarantee of access to any specific investigational compound by any individual.

Currently, participation in clinical trials is the only way for patients to gain access to CID-078. As more clinical data on the safety and efficacy of this investigational therapy becomes available, we will review and update our policy on Expanded Access.